RxDoctor Payments DataLook up a doctor →

John Boudreaux, MD

Surgery · Kenner, LANPI 1407879455

Payments from drug & device makers

$38,005in general payments, 2019–2025

Across 224 payments — averaging $169.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ipsen Biopharmaceuticals, Inc$10K
  • Biom'up SA$7K
  • Intuitive Surgical$7K
  • Advanced Accelerator Applications$5K
  • Sun Pharmaceutical Industries Inc.$2K
  • Biom'up France SAS$1K
  • plus $5K from 50 others

What the payments were for

  • Consulting fees$5,00013%
  • Speaking & faculty fees$16,06842%
  • Travel & lodging$3,86610%
  • Food & beverage$8,07121%
  • Education$5,00013%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$38,005 in reported general payments places this provider in the 90th percentile of 381 surgery providers in Louisiana.

See all surgery providers in Louisiana

Medicare billing

Part B allowed, 2024
$60,934
Medicare patients
128
Services billed
438

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase43$93,157
Everolimus24$78,439
Octreotide Acetate18$16,423
CholestyramineCholestyramine (With Sugar)24$1,824
Tacrolimus17$837
Clotrimazole18$719
Ursodiol12$299
Pantoprazole Sodium16$197
Allopurinol18$191
Gabapentin11$153
Calcitriol11$102
Tamsulosin Hcl14$92
Metoclopramide Hcl19$56
Tramadol Hcl15$33
Famotidine11$23

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon$216$93,15743 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 381 surgery providers in Louisiana.

Other surgery in Kenner

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →